EMA Authorised: Inbrija (levodopa) — Merz Therapeutics GmbH

View source ↗

Summary

The EMA authorised Inbrija (levodopa) by Merz Therapeutics GmbH for Parkinson disease. This marks EU market authorisation for an inhaled levodopa formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• INBRIJA (levodopa inhalation powder)

Snippet

Status: Authorised. Therapeutic area: Parkinson Disease. MAH: Merz Therapeutics GmbH. Decision date: 21/11/2025